Article Text

PDF
Electronic poster abstract
E-056 Endovascular treatment of medically refractory cerebral vasospasm following aneurysmal subarachnoid hemorrhage
  1. S Hetts1,
  2. P Jun1,
  3. N Ko2,
  4. J English3,
  5. C Dowd1,
  6. R Higashida1,
  7. V Halbach1
  1. 1Radiology, UCSF, California, USA
  2. 2Neurology, UCSF, California, USA
  3. 3Radiology and Neurology, UCSF, California, USA

Abstract

Background and purpose Cerebral vasospasm (CV) following aneurysmal subarachnoid hemorrhage (SAH) is a significant cause of morbidity and mortality. We review our experiences using percutaneous transluminal angioplasty (PTA) and intra-arterial (IA) verapamil infusion for treating medically refractory cases.

Materials and methods Retrospective review of SAH patients admitted from July 2003 to January 2008.

Results Of 546 patients admitted with SAH, 231 patients (42%) developed symptomatic CV and 189 patients (35%) required endovascular therapy. A total of 346 endovascular sessions were performed consisting of a single angioplasty, 286 IA verapamil infusions and 59 combined therapies. PTA was performed on 151 vessel segments and IA verapamil infused in 720 vessel segments. IA verapamil doses ranged from 2.0 to 30.0 mg per vessel segment and 3.0 to 55.0 mg per treatment session. Repeat treatments were necessary in 182 patients (96%) for persistent, recurrent or worsening CV. There were six treatment related complications (1.7%) of which two (0.6%) resulted in clinical worsening. No deaths were attributable to endovascular therapy. At follow-up, 115 patients (61%) had a good outcome and 55 patients (29%) had a poor outcome. Sixteen patients died from causes related to SAH while three died from other medical complications.

Conclusion Endovascular treatments are an integral part of managing patients with medically refractory CV. In our experience, PTA and IA verapamil are safe with a very low complication rate but further studies are required to determine appropriate patient selection and treatment efficacy.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.